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ABSTRACT
Organic anion-transporting polypeptides (OATPs) are multispecific
transporters mediating the uptake of endogenous compounds and
xenobiotics in tissues that are important for drug absorption and
elimination, including the intestine and liver. Silymarin is a popular
herbal supplement often used by patients with chronic liver disease;
higher oral doses than those customarily used (140 mg three times/
day) are being evaluated clinically. The present study examined the
effect of silymarin flavonolignans on OATP1B1-, OATP1B3-, and
OATP2B1-mediated transport in cell lines stably expressing these
transporters and in human hepatocytes. In overexpressing cell lines,
OATP1B1- and OATP1B3-mediated estradiol-17b-glucuronide uptake
and OATP2B1-mediated estrone-3-sulfate uptake were inhibited
by most of the silymarin flavonolignans investigated. OATP1B1-,
OATP1B3-, and OATP2B1-mediated substrate transport was inhibited
efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3mM, respectively),
silybin A (IC50 values of 9.7, 2.7 and 4.5 mM, respectively), silybin B
(IC50 values of 8.5, 5.0 and 0.8 mM, respectively), and silychristin (IC50
values of 9.0, 36.4, and 3.6 mM, respectively). Furthermore, silymarin,
silybin A, and silybin B (100 mM) significantly inhibited OATP-mediated
estradiol-17b-glucuronide and rosuvastatin uptake into human hep-
atocytes. Calculation of the maximal unbound portal vein concen-
trations/IC50 values indicated a low risk for silymarin-drug interactions
in hepatic uptake with a customary silymarin dose. The extent of
silymarin-drug interactions depends on OATP isoform specificity and
concentrations of flavonolignans at the site of drug transport. Higher
than customary doses of silymarin, or formulations with improved
bioavailability, may increase the risk of flavonolignan interactions with
OATP substrates in patients.
Introduction
Silymarin, a purified extract from milk thistle (Silybum marianum),
is a popular herbal supplement that is used by approximately one-third
of patients with hepatitis C infection or chronic liver disease because
of its reported hepatoprotective properties (Seeff et al., 2008; Freedman
et al., 2011). A standardized milk thistle extract contains at least 70%
silymarin, a complex mixture composed of mainly the flavonolignans
silybin A, silybin B, silydianin, silychristin, isosilybin A, isosilybin B,
and a few flavonoids, such as taxifolin (Wen et al., 2008) (Fig. 1).
Legalon SIL, a commercially available formulation of silybin A and
silybin B (silibinin dihemisuccinate), has been used clinically for
Amanita mushroom poisoning, resulting in reduced mortality rates,
compared with control-treated patients (Mengs et al., 2012). In vitro
studies suggest that silibinin dihemisuccinate inhibits organic anion-
transporting polypeptide (OATP)–mediated hepatic uptake of the
toxin amanitin (Letschert et al., 2006).
OATPs are important membrane transport proteins expressed in key
organs of drug disposition, including the intestine, liver, and kidneys,
where they mediate the cellular uptake of a broad range of xenobi-
otics and endogenous compounds. Two members of this family of
proteins, OATP1B1 and OATP1B3, are expressed predominantly in the
basolateral membrane of the hepatocyte (Hsiang et al., 1999; Konig
et al., 2000a). Other members, such as OATP2B1 and OATP1A2,
show broader tissue specificity; OATP2B1, for example, is expressed
in the intestine, placenta, brain, endothelial cells, and platelets (St-
Pierre et al., 2002; Kobayashi et al., 2003; Grube et al., 2006b;
Niessen et al., 2009). Substrates of OATP transport proteins include
widely prescribed drugs, such as 3-hydroxy-3-methylglutaryl co-
enzyme A reductase inhibitors (statins), angiotensin converting en-
zyme inhibitors, and antibiotics and anticancer drugs (Kobayashi
et al., 2003; Hirano et al., 2004; Nozawa et al., 2005; Smith et al.,
2005; Grube et al., 2006b; Ishiguro et al., 2006; Kitamura et al.,
2008). Furthermore, bile acids and steroid hormone conjugates are
endogenous substrates for these transporters (St-Pierre et al., 2002;
Hagenbuch and Meier, 2004).
Concomitant administration of inhibitors and substrates of OATPs
poses the risk of drug-drug interactions (DDIs), which can result in
changes in pharmacokinetics and an increased risk of adverse events
and/or reduced efficacy. Numerous studies investigating the effect of
genetic polymorphisms and DDIs have highlighted the impact of
altered hepatic OATP function on the pharmacokinetics of commonly
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used drugs. For example, coadministration of gemfibrozil, rifampicin,
or cyclosporine A with statins increased the area under the plasma
concentration-time profile of statins and the risk of developing rhab-
domyolysis; these changes in statin disposition have been attributed
primarily to decreased OATP-mediated hepatic uptake (Koenen et al.,
2011).
In addition to drugs, several herbal ingredients, such as flavonoids,
interact with drug uptake transport proteins of the OATP family. For
example, the flavonoids apigenin, quercetin, and kaempferol inhibit
the function of OATP1A2 and OATP2B1, which are localized in the
apical membrane of the intestine (Mandery et al., 2010). Furthermore,
green tea catechins, herbal extracts, and citrus and grapefruit juice
affect OATP-mediated transport (Satoh et al., 2005; Fuchikami et al.,
2006; Roth et al., 2011a,b).
In light of recent trends in the clinic toward the use of higher doses
and improved formulations of silymarin, the present study investigated
the influence of silymarin flavonolignans on the transport function
of the major hepatic OATP proteins, OATP1B1, OATP1B3, and
OATP2B1, to gain insights into possible herb-drug interactions. The
potential clinical implications of these findings are discussed.
Materials and Methods
Materials. [3H]Estrone-3-sulfate (E1S; 53.4 Ci/mmol) and [
3H]estradiol-
17b-glucuronide (E217G; 50.3 Ci/mmol) were purchased from Perkin Elmer
(Waltham, MA); [3H]rosuvastatin (10 Ci/mmol) was obtained from American
Radiolabeled Chemicals (St. Louis, MO). Unlabeled E1S, E217G, silymarin,
and bromosulfophtalein (BSP) were purchased from Sigma-Aldrich (St. Louis,
MO). Silychristin and silydianin were purchased from ChromaDex (Santo
Anna, CA) and U.S. Pharmacopoeia (Rockville, MD), respectively. Isosilybin
A and isosilybin B were a generous gift from Ulrich Mengs (Madaus GmbH,
Germany). Silybin A and silybin B were isolated and purified as previously
described (Graf et al., 2007). Cell culture supplies were purchased from Gibco
(Life Technologies, Grand Island, NY). Dimethyl sulfoxide was purchased
from Fisher Scientific (Fairlawn, NJ). Bio-Safe II liquid scintillation mixture
was obtained from Research Products International (Mt. Prospect, IL). All other
materials were purchased from Sigma-Aldrich (St. Louis, MO) or Invitrogen
(Carlsbad, CA). Silymarin flavonolignans were dissolved in dimethyl sulfoxide,
and stock solutions were stored at 220°C.
Cell Culture. The human embryonic kidney (HEK) 293-Mock, HEK293-
OATP1B3, and HEK293-OATP1B1 cell lines were kindly provided by Dr.
Dietrich Keppler (German Cancer Research Center, Germany). The MDCKII-
OATP2B1 cell line was kindly provided by Dr. Markus Grube (University
of Greifswald, Germany). HEK293-OATP1B1, HEK293-OATP1B3 and
HEK293-Mock, MDCKII-OATP2B1, and the parental MDCKII cell lines
were grown in 75 cm2 cell culture flasks in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10 mM L-glutamine and 10% fetal calf serum.
The transfected cell lines were maintained in medium containing 350 mg/ml
Hygromycin B (MDCKII cell lines) or 600 mg/ml G418 (HEK293 cell
lines). Cells were incubated at 37°C in a humidified atmosphere containing
5% CO2.
Freshly isolated human hepatocytes provided by Life Technologies
(Durham, NC) and Triangle Research Laboratories, LLC (Research Triangle
Park, NC), were seeded in 24-well plates at a seeding density of 350,000 cells
per well in DMEM containing 5% (v/v) fetal bovine serum, 10 mM insulin,
1 mM dexamethasone, 1% (v/v) minimum essential medium nonessential amino
acids, 2 mM L-glutamine, 100 units penicillin G, and 100 mg of streptomycin
sulfate (seeding medium). After 1 hour incubation at 37°C, 5% CO2 in a humidified
incubator, medium was aspirated to remove dead and unattached cells and
replaced with fresh seeding medium. At day 1, either an uptake experiment was
performed or hepatocytes were overlaid with Matrigel (0.25 mg/ml) and
cultured in DMEM containing 1% insulin/transferrin/selenium (ITS + premix),
0.1 mM dexamethasone, 2 mM L-glutamine, 1% MEM nonessential amino acids,
100 units of penicillin G, and 100 mg of streptomycin; medium was changed
every day. Human hepatocytes were cultured up to 8 days to allow polarization
and canalicular network formation. The demographic characteristics of the human
liver donors are shown in Table 1.
Transport Assays. For transport studies using cell lines, cells were seeded
in 24-well plates and cultured to confluence; after removing the medium, cells
were washed twice with phosphate-buffered saline and incubated at 37°C with
Fig. 1. Chemical structure of silymarin flavonoli-
gnans. The composition of individual flavonolignans
in silymarin is indicated in parentheses.
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Hank’s balanced salt solution (HBSS) containing the substrate (pH 7.4). At
specified time points, the transport buffer was aspirated rapidly, and cells were
washed four times with ice-cold HBSS. Cells were solubilized in 0.5% Triton
X-100 in phosphate-buffered saline, an aliquot was dissolved in 2 ml scintillation
cocktail, and samples were measured in a scintillation b-counter. In all cases, the
amount of substrate transported was normalized for protein content determined
by the bicinchoninic acid protein assay. To determine the concentration-
dependent effects of compounds on OATP-mediated uptake, experiments were
performed as described above, except that specified concentrations of silymarin
and silymarin flavonolignans (0–100 mM) were used.
For hepatocyte experiments, hepatocytes were rinsed twice with HBSS at
37°C. Subsequently, hepatocytes were incubated with [3H]rosuvastatin (0.5
mM, 1.5 minutes) or [3H]E217G (1 mM, 1 minute) in the presence of test
compound or vehicle in HBSS at 37°C. After incubation, the dosing solution
was aspirated and cells were washed 3 times with ice-cold HBSS. Cells were
lysed in 0.2 ml of 0.5% (v/v) Triton-X100 in phosphate-buffered saline, and an
aliquot was measured in a scintillation b-counter.
Because substrate uptake experiments were performed under sink conditions,
apparent hepatic uptake clearance (CLuptake,app) of substrates, which includes
total cellular accumulation resulting from passive diffusion, active transport,
binding, and/or membrane partitioning, was calculated according to Eq. 1:
CLuptake;app ¼ AccumulationHepatocytesCincubation bufferpincubation time ð1Þ
Inhibition of OATP-mediated uptake of E217G and rosuvastatin by silymarin
flavonolignans in human hepatocytes was determined after subtraction of the
non–OATP-mediated component of accumulation, which was determined as
the accumulation of the respective substrate in the presence of 100 mM BSP (an
inhibitor of OATPs). For each experiment, this OATP-mediated accumulation
value was set at 100%, data were expressed as a percentage of vehicle control,
and the mean and S.E.M. of three experiments was reported. Uptake was
corrected for nonspecific binding by incubating collagen-coated wells without
hepatocytes. Furthermore, accumulation and clearance values were normalized
for protein content measured by bicinchoninic acid protein assay.
Statistics. The OATP-mediated net uptake was calculated by subtracting the
substrate uptake in the parental cell lines (OATP-negative) from the uptake in
OATP-expressing cells. Uptake inhibition, presented as percentage of control,
was calculated from control experiments in the presence of vehicle, which was
set as 100% uptake. Results are presented as mean 6 S.D., mean 6 range, or
mean 6 S.E.M., as indicated. The half-maximal inhibitory concentration (IC50)
values were calculated by fitting dose-response curves to the data by nonlinear
regression using Prism software 5.0 (GraphPad Software Inc., La Jolla, CA),
with use of three models: (1) four parameter fit, (2) three parameter fit with
a fixed bottom, and (3) three parameter fit with a fixed top. IC50 values are
reported from the model that best described each data set based on goodness of
fit parameters.
Statistical analysis of the data was conducted using a repeated-measures
analysis of variance, followed by Dunnet’s post hoc test. Differences were
considered to be statistically significant when P # 0.05.
Estimation of Portal Vein Concentrations. Maximal unbound portal vein
concentrations (Cu,max,in) were estimated using the method described by Ito et al.
to assess the relevance of the inhibitory effect of silymarin flavonolignans on the
transport function of the investigated OATPs according to Eq. 2 (Ito et al., 1998):
Cu;max;in ¼ ðCmax þ ðkapDÞQ pFa

*  fu ð2Þ
The maximal plasma concentration (Cmax), the dose (D), the fraction absorbed
from the gastrointestinal tract (Fa), and hepatic blood flow (Q) were obtained
from the literature (Table 3). We previously determined an absorption rate
constant (ka) of 0.669 hour
21 for silybin A in patients with liver disease with
use of a population pharmacokinetic approach (unpublished data). However,
because this study was conducted in a diseased population and the absorption
rate constant (ka) for other silymarin flavonolignans has not been described in
the literature, ka was set to the theoretical maximal value (0.1 minute
21, which
is the maximal gastric emptying rate constant in humans) (Table 3). The
fraction unbound (fu) of silibinin (silybin A and silybin B 1:1) was 0.05-0.1
(personal communication. Dr. Ulrich Mengs, Madaus GmbH).
Results
Characterization of OATP-Overexpressing Cell Lines. HEK293-
OATP1B1, HEK293-OATP1B3, and MDCKII-OATP2B1 cells have
been described previously (Konig et al., 2000a,b; Grube et al., 2006a).
Uptake of E1S (1 mM; OATP2B1) and E217G (1 mM; OATP1B1 and
OATP1B3) was linear up to 5 minutes (unpublished data). Therefore,
subsequent experiments using these cell lines were performed at 3
minutes.
Influence of Silymarin Flavonolignans on OATP-Mediated Uptake
in Overexpressing Cell Lines. To determine the effect of silymarin
on OATP function, OATP-mediated uptake of E217G (OATP1B1,
OATP1B3) and E1S (OATP2B1) was measured in the presence of
silymarin or individual silymarin flavonolignans (10 mM each). As illus-
trated in Fig. 2, all tested silymarin flavonolignans significantly inhibited
OATP2B1-mediated E1S uptake. For OATP1B1, all flavonolignans
except silychristin significantly inhibited E217G uptake, whereas
OATP1B3-mediated E217G transport was significantly inhibited only
by silybin A, isosilybin B, silydianin, and silymarin.
The concentration-dependent inhibition of OATP-mediated sub-
strate uptake was investigated further for silymarin and the individual
flavonolignans silybin A, silybin B, and silychristin, which are the
main constituents of silymarin, each comprising up to 35% of the
mixture. As shown in Fig. 3 and Table 2, the interaction of individual
silymarin flavonolignans with OATP2B1, compared with inhibition of
OATP1B1- and 1B3-mediated substrate uptake, appeared to be very
potent, in general. Silymarin was the strongest inhibitor of all OATPs
(IC50 values of 1.3, 2.2, and 0.3 mM for OATP1B1, OATP1B3, and
OATP2B1, respectively). Silybin B inhibited OATP2B1 uptake more
than silybin A or silychristin (IC50 values of 0.8 mM versus 4.5 mM
and 3.6 mM, respectively). Silybin A, silybin B, and silychristin were
almost equipotent in inhibiting OATP1B1-mediated substrate uptake,
whereas OATP1B3-mediated substrate uptake was inhibited more
strongly by silybin A and silybin B (IC50 values of 2.7 and 5.0 mM,
respectively), compared with silychristin (IC50 value of 36.4 mM).
Estimation of Portal Vein Concentrations. To evaluate the
potential impact of silymarin flavonolignans on inhibition of hepatic
OATPs, maximal unbound portal vein concentrations (Cu,max,in) were
estimated on the basis of a method described by Ito et al. (Ito et al.,
1998). Because the absorbed fraction of silymarin flavonolignans in
humans has not been reported, absolute bioavailability data from rats
were used under the assumption that the fraction absorbed is at least
equal to absolute bioavailability and similar in rat and human. To
determine the inhibition potential for hepatic OATPs, the unbound
fraction must also be taken into account. Although no protein binding data
have been reported in humans for these compounds, the protein binding of
silibinin (silybin A and silybin B) is 70% in rat (Wu et al., 2007). With use
of the ADMET predictor, the unbound fraction of silybin A and silybin B
was estimated to be approximately 1.5% in humans. An unbound fraction
of 5%–10% in human plasma was determined experimentally for silibinin
(silybin A and B 1:1) (personal communication, Dr. Ulrich Mengs,
TABLE 1
Demographic characteristics of human liver donors
Donor Sex Race Age BMI Alcohol/Smoking
Hu1369 Female White 47 19.4 1 Beer/day
Hu1416 Male White 58 28.1 —
Hu1434 Male White 55 25.6 Yes
RTL Hu 4014 Male White 20 19 Not reported
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Madaus GmbH). To calculate the unbound portal vein concentration an
unbound fraction of 5% was assumed (Table 3).
Influence of Silymarin Flavonolignans on E217G and Rosuvas-
tatin Uptake in Human Hepatocytes. E217G and rosuvastatin were
used to investigate the effect of silymarin, silybin A, and silybin B on
OATP-mediated uptake in human hepatocytes. BSP, a potent inhibitor
of OATPs, was used to assess passive permeation and other active
uptake processes in the absence of OATP-mediated substrate trans-
port. BSP (100 mM) decreased substrate uptake into OATP1B1-,
OATP1B3-, and OATP2B1-overexpressing cell lines to values observed
in the parental cell lines (unpublished data).
In sandwich-cultured human hepatocytes, the apparent uptake
clearance of E217G was 9.7 and 7.5 ml/mg protein/min for day 1 and 8
of culture, respectively. For rosuvastatin, apparent uptake clearance
values of 52.6 ml/mg protein/min and 21.7 ml/mg protein/min on days 1
and 8, respectively, were observed. BSP inhibited the apparent uptake
clearance of E217G in sandwich-cultured hepatocytes to ;45% and
;60% of control values on day 1 and day 8 of culture, respectively;
BSP inhibited the apparent uptake clearance of rosuvastatin to ;25%
and ;36% of uptake in control-treated cells on day 1 and day 8 of
culture, respectively. These data suggested that some passive diffusion,
non–OATP-mediated transport and/or binding/partitioning processes
were involved in accumulation of these probe substrates (Fig. 4, A and
B). On day 1, OATP-mediated uptake of E217G and rosuvastatin was
inhibited significantly by silymarin, silybin B, and silybin A (100 mM)
and 10 mM silymarin (Fig. 4, C and D). Similar results were obtained
for sandwich-cultured hepatocytes on day 8; however, in contrast to day
1, the E217G uptake was not significantly inhibited by silybin A at
Fig. 2. Effect of silymarin flavonolignans on OATP-mediated substrate uptake. Cells were incubated with [3H]E217G (1 mM; OATP1B1, OATP1B3) or [
3H]E1S (1 mM,
OATP2B1) and 10 mM of the flavonolignans indicated or with the vehicle control for 3 minutes at 37°C. OATP-mediated uptake was calculated after correcting for protein
by subtracting uptake into empty vector (OATP1B1, OATP1B3) or nontransfected control cells (OATP2B1). Values are expressed as a percentage of control; each value is
presented as the mean 6 S.D. of at least three independent experiments performed in triplicate. *P # 0.05, compared with control.
Fig. 3. Concentration-dependent modulation of E1S and E217G uptake into OATP-overexpressing cell lines by silymarin and silymarin flavonolignans. Cells were
coincubated with silymarin flavonolignans (0–100 mM) and [3H]E1S (0.25 mCi/ml; 1 mM; OATP2B1) or [
3H]E217G (0.25 mCi/ml; 1 mM; OATP1B1, OATP1B3) for 3
minutes at 37°C. Values are expressed as percentage of vehicle control; each value represents the mean 6 range of two independent experiments performed in duplicate.
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a concentration of 100 mM (inhibition to 58% 6 35% of control)
(unpublished data).
Discussion
Silymarin, the extract of milk thistle, is widely used as a dietary
supplement by patients with liver and biliary tract disease because of
its reported hepatoprotective properties. Because of the common
perception that herbal supplements are generally safe, silymarin is
often comedicated with conventional drugs, raising the potential for
herb-drug interactions. Members of the OATP family of transport
proteins are responsible for the hepatic uptake of many clinically
important drugs, including statins, angiotensin-converting enzyme
inhibitors, and anticancer therapeutics, and some endogenous com-
pounds, such as bilirubin. Several clinical studies have shown that the
activity of these transporters can determine the efficacy and adverse
events of drugs (Koenen et al., 2011). Therefore, the goal of the
present study was to investigate the interaction potential of individual
constituents of silymarin extract with hepatic OATPs to gain insights
into possible silymarin-drug interactions.
The present study indicated that silymarin flavonolignans signifi-
cantly inhibited OATP transport in overexpressing cell lines and
human hepatocytes (Figs. 2–4). Of interest, despite the structural
similarity and identical molecular weight (Fig. 1), the individual
silymarin flavonolignans differentially inhibited OATP-mediated trans-
port. These findings suggest that stereo- and regiochemistry modify the
interaction potential with OATP transport proteins; IC50 values varied
by ;10-fold among the individual flavonolignans (Table 2). This is
consistent with results reported from recent clinical and in vitro
metabolism studies in which the diastereomers of silybin (A and B),
and the isomers isosilybin A and isosilybin B exhibited different
pharmacokinetic properties and inhibition potential for CYP-mediated
metabolism (Brantley et al., 2010; Hawke et al., 2010).
To assess the clinical interaction potential of drugs/compounds with
uptake transport proteins, the International Transporter Consortium
recently recommended a cutoff value of [I]/IC50 . 0.1, where [I]
represents the inhibitor concentration, for performing in vivo drug
interaction studies (Giacomini et al., 2010). Of note, the total (bound
and unbound) systemic concentrations of silymarin flavonolignans are
generally low. The maximal steady-state concentrations (Cmax) of total
unconjugated silybin A and silybin B, after a dose of 140 mg of
silymarin three times per day in patients with chronic hepatitis C was
40 ng/ml (0.08 mM) and 8 ng/ml (0.016 mM), respectively, which is at
least 10-fold lower than the IC50 values reported for OATP inhibition
in the current study (Hawke et al., 2010). However, in a recently
completed large, placebo-controlled clinical trial in patients with
hepatitis C virus infection receiving silymarin doses of 420 and 700
mg three times per day, plasma concentrations up to 2048 ng/ml (4.2
mM) were observed for silybin A (Fried et al., 2012). Assuming an
unbound fraction of 5%, the unbound concentration of silybin A
achieved in this clinical study was approximately 10–50-fold lower
than the concentrations associated with the IC50 values observed for
inhibition of OATP-mediated uptake in the present study. Because the
low customary doses of silymarin, which are used by patients with
liver disease, do not achieve high systemic concentrations of silymarin
flavonolignans, the potential for DDIs appears to be low. However,
systemic concentrations may not be the best measure to assess the
interaction potential with hepatic uptake transport proteins; for com-
pounds that undergo extensive presystemic elimination, unbound
portal vein concentrations are more applicable. On the basis of
estimated unbound portal vein concentrations (Ito et al., 1998), the
silybin B concentrations after high-dose silymarin supplementation
are within the same micromolar range as the IC50 value determined
for inhibition of OATP2B1 (Tables 2 and 3). Furthermore, the over-
all lower IC50 values for silymarin, compared with the individual
flavonolignans, suggest that there might be synergy between the
silymarin constituents with respect to OATP inhibition. However,
because of differential pharmacokinetics of these compounds, the
actual unbound portal vein concentrations of each component are
difficult to assess in humans. On the basis of estimations, the maximal
total unbound portal vein concentrations of the major flavonolignans
in the systemic circulation (silybin A and silybin B) add up to ;0.17
TABLE 2
IC50 values and 95% confidence intervals (CIs) for inhibition of OATP-mediated
transport (E217G for OATP1B1 and OATP1B3 and E1S for OATP2B1)
Cell Line Compound IC50 95% CI
mM
OATP1B1 Silymarin 1.3a 1.0–1.6
Silybin A 9.7b 5.3–17.7
Silybin B 8.5b 5.6–12.9
Silychristin 9.0b 6.0–13.4
OATP1B3 Silymarin 2.2c 1.1–4.7
Silybin A 2.7c 0.7–11.0
Silybin B 5.0c 0.5–52.4
Silychristin 36.4c 1.6–855
OATP2B1 Silymarin 0.3a 0.2–0.7
Silybin A 4.5b 2.7–7.8
Silybin B 0.8b 0.6–1.1
Silychristin 3.6a 2.5–4.0
a Four parameter fit.
bThree parameter fit with fixed bottom.
c Three parameter fit with fixed top; IC50 values were estimated from a maximal inhibition that
was less than 100%.
TABLE 3
Estimation of portal vein concentrations for individual parent flavonolignans
A bold [I]/IC50 number indicates that the value is above the cutoff of 0.1.
Variable Silybin A Silybin B Reference
Dose of silymarin (mg) 700 140 700 140 (Hawke et al., 2010)
[Dose of individual flavonolignans (mg)] [116] [23.2] [160] [32]
Cmax (mg/ml) 0.58 0.04 0.22 0.008 (Hawke et al., 2010)
ka (Absorption rate constant; min
21) 0.1 (Ito et al., 1998)
Q (Hepatic blood flow; ml/min) 1500 (Wynne et al., 1989)
fu (Fraction unbound) 0.05 Dr. Mengs, Madaus GmbH, Germany
fa (Fraction absorbed) 0.2 0.62 From rat (Pade, 2007)
Cu,max,in (unbound portal vein conc.; mM) 0.22 0.04 0.70 0.13 Calculated
[I]/IC50 ratio OATP1B1 0.02 0.004 0.08 0.02 Calculated
[I]/IC50 ratio OATP1B3 0.08 0.01 0.14 0.03 Calculated
[I]/IC50 ratio OATP2B1 0.05 0.01 0.88 0.16 Calculated
962 Köck et al.
and 0.92 mM for a dose of 140 mg and 700 mg silymarin, respectively;
the [I]/IC50 ratio observed for inhibition of OATP-mediated transport
by silymarin (IC50 values of 1.3, 2.2, and 0.3 mM for OATP1B1,
OATP1B3, and OATP2B1, respectively) yielded values that were
above the cutoff of 0.1 recommended by the International Transporter
Consortium to initiate further studies to assess the interaction potential
with uptake transport proteins. Other flavonolignans present in the
silymarin extract were excluded from this calculation, because their
systemic exposure is negligible after oral silymarin administration.
However, this does not exclude the possibility that portal concen-
trations of these flavonolignans could be significant and contribute to
inhibition of OATPs.
Several in vivo studies have investigated the interaction between
silymarin and drugs, such as digoxin, nifedipine, indinavir, ranitidine,
and rosuvastatin (Wu et al., 2009). Of those drugs, only digoxin and
rosuvastatin have been described as OATP substrates, although the
role of OATPs in digoxin transport has been questioned (Taub et al.,
2011). Silymarin administration (140 mg three times per day) did not
affect the pharmacokinetics of the OATP substrate rosuvastatin in
healthy subjects, despite inhibition of OATP1B1 function by silymarin
in OATP1B1-overexpressing oocytes (Deng et al., 2008). The authors
concluded that pretreatment with silymarin does not result in a risk for
drug interactions between silymarin and rosuvastatin in vivo. However,
in the study by Deng et al., a customary dose of 140 mg silymarin
was administered three times daily. We previously demonstrated that
silymarin flavonolignans do not reach peak plasma concentrations
above 0.2 mM with use of this dose regimen (Hawke et al., 2010); these
concentrations are significantly lower than those associated with drug
interaction risk identified in the present study. However, higher oral
doses and improved formulations of silymarin (e.g., nanoemulsions) are
being evaluated to increase systemic/tissue concentrations to achieve
desired clinical outcomes (Flaig et al., 2010; Li et al., 2010; Wang et al.,
2012). On the basis of the present study, these higher doses and/or
improved formulations may increase the risk of OATP-mediated
interactions.
In hepatocytes at day 1 of culture, 100 mM silymarin, silybin A, or
silybin B significantly inhibited E217G and rosuvastatin transport.
These concentrations were above the observed IC50 value for all
investigated OATPs; thus, almost complete ablation of OATP-
mediated transport would be expected. Silymarin and individual
flavonolignan concentrations of 10 mM are close to the observed IC50
values for OATP inhibition, resulting in less pronounced inhibition of
transport (Fig. 4; Table 2). Indeed, for silybin B, no significant
reduction in substrate uptake was observed. To assess the overall
effect on hepatic substrate uptake, it is important to appreciate the
contribution of individual transport proteins to substrate uptake, the
relative protein expression levels, and the potency of the inhibitor
toward the respective transport protein. For example, OATP1B1 is
primarily involved in rosuvastatin uptake, with only 16–34% attribut-
able to OATP1B3. Because of the lower expression levels of OATP2B1
Fig. 4. Inhibition of OATP-mediated E217G and rosuvastatin accumulation in sandwich-cultured human hepatocytes by silymarin and silymarin flavonolignans. (A and B)
Apparent uptake clearance (CLuptake,app) of E217G (0.25 mCi/ml; 1 mM, 1 minute) and rosuvastatin (0.05 mCi/ml; 0.5 mM, 1.5 minute) in sandwich-cultured human
hepatocytes on day 1 and day 8 of culture determined in the absence (control, solid bars) or presence (hatched bars) of 100 mM BSP. Values represent the mean 6 S.E.M. of
three (rosuvastatin) or four (E217G) independent experiments performed in triplicate. (C and D) Human hepatocytes (day 1) were coincubated with silymarin flavonolignans
and [3H]E217G (0.25 mCi/ml; 1 mM) for 1 minute or [
3H]rosuvastatin (0.05 mCi/ml; 0.5 mM) for 1.5 minute at 37°C. To calculate OATP-mediated uptake, substrate
accumulation was determined in the presence of 100 mM BSP; after subtraction of this value, accumulation in the presence of silymarin or silymarin flavonolignans was
expressed as a percentage of vehicle control. Values represent the mean 6 S.E.M. of three independent experiments performed in triplicate. *P # 0.05, compared with control.
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in hepatocytes, the contribution of this transport protein to hepatic
uptake of rosuvastatin was deemed to be negligible (Kitamura et al.,
2008). However, for other substrates, the contribution of the individual
transport proteins might differ. Compounds will affect the overall
substrate uptake differently, based on their inhibition potential for the
individual proteins, which was highlighted by predictions in the study
by Karlgren et al. (2012).
Because of the low estimated portal vein concentrations (Table 3),
interaction with hepatic OATP-mediated uptake processes is relatively
unlikely, especially at the low dose of silymarin recommended for
supplementary use. However, our results demonstrate that silymarin
flavonolignans not only inhibit OATP1B1 but also OATP2B1. While
OATP1B1 and OATP1B3 are expressed almost exclusively in he-
patocytes, OATP2B1 exhibits ubiquitous expression and localization
in the apical plasma membrane of enterocytes, where this transport
protein is believed to play an important role in uptake of substrates
from the intestinal lumen into enterocytes (Nozawa et al., 2004). A
dose containing 140 mg of silymarin extract as a dietary supplement
would result in a theoretical maximal gastrointestinal concentration of
;1 mM if taken with 250 ml water. Because of silymarin’s low water
solubility of 0.4 mg/ml (Woo et al., 2007), concentrations in the range
of 0.8 mM may be more realistic. Regardless, the estimated maximal
gastrointestinal concentration of silymarin is significantly greater than
the IC50 for OATP2B1 inhibition, which could result in lower bio-
availability of OATP2B1 substrates when administered orally with
silymarin. Although drugs that are predominately absorbed by an
OATP2B1-mediated process have yet to be identified, current drugs
that may be partly dependent on OATP2B1-mediated transport
include aliskiren, montelukast, and glibenclamide (Vaidyanathan
et al., 2008; Mougey et al., 2009, 2011; Tapaninen et al., 2011).
Recently, scutallarin, an active flavonoid in Erigheron brevisacapus
extract was demonstrated to be a specific substrate for OATP2B1 (Gao
et al., 2012).
In conclusion, the present data suggest that silymarin flavonoli-
gnans inhibit the transport of OATP substrates in overexpressing cell
lines and in human hepatocytes. Estimations of the maximal portal
vein concentrations indicate a low risk for silymarin-drug interactions
at the hepatic transport protein level, especially at the recommended
silymarin dose of 140 mg. However, the use of higher silymarin doses
or silymarin formulations with improved bioavailability might increase
portal vein concentrations and, thus, may increase the risk of OATP-
mediated drug interactions.
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